Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
Bone Marrow Transplantation|April 7, 2021
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world dataTalha Badar, Aniko Szabo, Mark Litzow, et al.Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyBijal Shah, Ryan J Mattison, Ramzi Abboud, et al.The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJeffrey Crawford, Pamela Sue Becker, James O Armitage, et al.Pageof 4